Pediatric drug trials facing some obstacles.
Finkelstein
Joel B
JB
D000227:Adenine Nucleotides; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001087:Arabinonucleosides / Q000627:therapeutic use; D002648:Child; D002986:Clinical Trials as Topic / Q000592:standards*; D000077866:Clofarabine; D004341:Drug Evaluation / Q000592:standards; D004345:Drug Industry / Q000331:legislation & jurisprudence / Q000592:standards; D015507:Drugs, Investigational / Q000627:therapeutic use*; D051523:Fibroblast Growth Factor 7 / Q000627:therapeutic use; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006801:Humans; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D014481:United States; D014486:United States Food and Drug Administration
D000227:Adenine Nucleotides; D000970:Antineoplastic Agents; D001087:Arabinonucleosides; D015507:Drugs, Investigational; D011994:Recombinant Proteins; D051523:Fibroblast Growth Factor 7; D016179:Granulocyte Colony-Stimulating Factor; C455861:pegfilgrastim; D011092:Polyethylene Glycols; D000077866:Clofarabine; D000069585:Filgrastim